Healthcare | May 08, 2024
Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia
Investing in Malaysia's largest clinic operator to expand the healthcare business
Investing in Malaysia's largest clinic operator to expand the healthcare business
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
With this, for all our USFDA facilities, EIRs are in place
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The project funding will be done through a mix of internal accruals and debts.
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Subscribe To Our Newsletter & Stay Updated
